Rush | Strategic Alliance Partners

Latest from Rush

Sequencing Strategies Shift in Metastatic HER2+ Breast Cancer

February 01, 2022

Ruta D. Rao, MD, discusses factors that inform treatment selection for patients with metastatic HER2-positive breast cancer, the effects key data that emerged in 2021 have had on sequencing, strategies to mitigate toxicities associated with trastuzumab deruxtecan, and remaining questions regarding sequencing that may be the focus of ongoing research effort.

Dr. Rao on Abemaciclib Post-Palbociclib in Metastatic Breast Cancer

June 20, 2019

Ruta Rao, MD, associate professor of medical oncology, Rush University Medical Center, discusses the use of abemaciclib with or without fulvestrant for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer following prior treatment with palbociclib.

Dr. Jain on Results of Gender Disparities Study in Oncology

June 18, 2019

Shikha Jain, MD, hematologist/oncologist, Rush University Medical Center, discusses the disparities between male and female professionals at medical conferences, specifically the American Society of Clinical Oncology (ASCO) Annual Meeting.

Dr. Fidler on Novel Chemotherapy Strategies in Nonsquamous NSCLC

June 18, 2019

Mary J. Fidler, MD, associate professor, Rush University Medical Center, discusses progression-free survival (PFS) and overall survival (OS) in patients with stage IV, nonsquamous, non–small cell lung cancer patients (NSCLC) treated with first-line pemetrexed and platinum followed by pemetrexed maintenance.

Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

April 05, 2019

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

HER2+ Breast Cancer Paradigm Slated to Expand With Novel Therapies

March 26, 2019

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

Using Recurrence Risk to Tailor Treatment in HR+/HER2- Breast Cancer

March 25, 2019

Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC

October 07, 2017

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.